Glasdegib Plus Intensive/Nonintensive Chemotherapy in Untreated Acute Myeloid Leukemia: BRIGHT AML 1019 Phase III Trials
Jörge E. Cortes(Augusta University Health), Mikkael A. Sekeres(University of Miami), Christine DiRienzo(Pfizer (United States)), Xiaoxi Zhang(Pfizer (United States)), Timothy Bell(Pfizer (United States)), M. Naveed Shaik(Pfizer (United States)), Akil Merchant(University of Southern California), Tetsuzo Tauchi(Midorigaoka Hospital), Geoffrey Chan(The University of Texas System), Hervé Dombret(University of London Institute in Paris), Barbara Sleight(Pfizer (United States)), Eric Leip(Massachusetts General Hospital)
Cited by 48
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k